Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function

Possible links between diabetes and atherosclerosis

Fatemeh Moheimani, Philip E. Morgan, David M. van Reyk, Michael J. Davies

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

People with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for 8. weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of proteasome activity by glycated proteins may result in further intracellular accumulation of glycated proteins with subsequent deleterious effects on cellular function.

Original languageEnglish
Pages (from-to)561-571
Number of pages11
JournalBiochimica et Biophysica Acta - Molecular Basis of Disease
Volume1802
Issue number6
DOIs
Publication statusPublished - 1 Jun 2010

Fingerprint

Aldehydes
Atherosclerosis
Macrophages
Advanced Glycosylation End Products
Proteasome Endopeptidase Complex
Pyruvaldehyde
Glucose
Proteins
Enzymes
Glyoxal
Chymotrypsin
Caspases
Cell Extracts
Hyperglycemia
glycolaldehyde

Cite this

@article{7d07c039e3644603838858a477f9be1b,
title = "Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function: Possible links between diabetes and atherosclerosis",
abstract = "People with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for 8. weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of proteasome activity by glycated proteins may result in further intracellular accumulation of glycated proteins with subsequent deleterious effects on cellular function.",
author = "Fatemeh Moheimani and Morgan, {Philip E.} and {van Reyk}, {David M.} and Davies, {Michael J.}",
year = "2010",
month = "6",
day = "1",
doi = "10.1016/j.bbadis.2010.02.007",
language = "English",
volume = "1802",
pages = "561--571",
journal = "Biochimica et Biophysica Acta - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "6",

}

Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function : Possible links between diabetes and atherosclerosis. / Moheimani, Fatemeh; Morgan, Philip E.; van Reyk, David M.; Davies, Michael J.

In: Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1802, No. 6, 01.06.2010, p. 561-571.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Deleterious effects of reactive aldehydes and glycated proteins on macrophage proteasomal function

T2 - Possible links between diabetes and atherosclerosis

AU - Moheimani, Fatemeh

AU - Morgan, Philip E.

AU - van Reyk, David M.

AU - Davies, Michael J.

PY - 2010/6/1

Y1 - 2010/6/1

N2 - People with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for 8. weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of proteasome activity by glycated proteins may result in further intracellular accumulation of glycated proteins with subsequent deleterious effects on cellular function.

AB - People with diabetes experience chronic hyperglycemia and are at a high risk of developing atherosclerosis and microvascular disease. Reactions of glucose, or aldehydes derived from glucose (e.g. methylglyoxal, glyoxal, or glycolaldehyde), with proteins result in glycation that ultimately yield advanced glycation end products (AGE). AGE are present at elevated levels in plasma and atherosclerotic lesions from people with diabetes, and previous in vitro studies have postulated that the presence of these materials is deleterious to cell function. This accumulation of AGE and glycated proteins within cells may arise from either increased formation and/or ineffective removal by cellular proteolytic systems, such as the proteasomes, the major multi-enzyme complex that removes proteins within cells. In this study it is shown that whilst high glucose concentrations fail to modify proteasome enzyme activities in J774A.1 macrophage-like cell extracts, reactive aldehydes enhanced proteasomal enzyme activities. In contrast BSA, pre-treated with high glucose for 8. weeks, inhibited both the chymotrypsin-like and caspase-like activities. BSA glycated using methylglyoxal or glycolaldehyde, also inhibited proteasomal activity though to differing extents. This suppression of proteasome activity by glycated proteins may result in further intracellular accumulation of glycated proteins with subsequent deleterious effects on cellular function.

UR - http://www.scopus.com/inward/record.url?scp=77952243282&partnerID=8YFLogxK

U2 - 10.1016/j.bbadis.2010.02.007

DO - 10.1016/j.bbadis.2010.02.007

M3 - Article

VL - 1802

SP - 561

EP - 571

JO - Biochimica et Biophysica Acta - Molecular Basis of Disease

JF - Biochimica et Biophysica Acta - Molecular Basis of Disease

SN - 0925-4439

IS - 6

ER -